Single Patient Classifier (SPC) Prediction for Stage II and III Advanced Gastric Cancer
NCT ID: NCT04600518
Last Updated: 2024-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2047 participants
OBSERVATIONAL
2020-10-07
2023-06-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pilot Clinical Study to Evaluate the Feasibility of Using the SPC Test
NCT06521528
Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer
NCT00821990
Study of ARQ 197 Monotherapy
NCT01152645
Prospective Assessment of nProfiler® 1 on Prognosis and Chemotherapy Response for Gastric Cancer
NCT04487717
A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
NCT03707028
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The goal of this study, a retrospective, multi-center, single-blind, pivotal trial, is to assess clinical equivalence with stage II and III advanced gastric cancer based on the 6th and 8th of the AJCC and to evaluate prognostic equivalence between surgery only group and adjuvant chemotherapy group in Low risk group.
The study will follow these procedures; Sample screening, Sample Preparation and Sample Criteria Evaluation, Sample enrollment, nProfiler® 1 Stomach Cancer Assay (gastric cancer prognosis prediction), Prognostic Result Report, and Evaluation of Clinical Performance.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SPRINT cohort
stage II and III advanced gastric cancer patients based on the 6th and 8th of the AJCC
nProfiler I Stomach Cancer Assay Kit
nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
nProfiler I Stomach Cancer Assay Kit
nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and female adult patients aged 19 years or over
* Postoperative patients with gastric cancer invading the submucosal layer and having 3 or more lymph nodes metastasis or who with gastric cancer infiltration of muscularis propria and lymph node metastasis (stage II and III advanced gastric cancer patients, 8th of the AJCC)
* Patients who have not received neoadjuvant chemotherapy and radiotherapy
* Patients with pathological record and clinical information after surgery from archived FFPE(formalin-fixed paraffin-embedded) samples between 2005 and 2010
* Patients who have not been included in discovery clinical trial and confirmatory clinical trial
* Patients who have undergone a radical gastrectomy and who show no evidence of residual tumors as observed with the unaided eye or through a microscope
2. Sample criteria
* The FFPE tumor specimens in storage have a tumor amount of at least 20% and therefore can be tested.
* The quantity (not less than 400ng) and quality (A260/280 of not less than 1.8) of RNA are sufficient for analysis.
Exclusion Criteria
* Male and female patients aged less than 19 years
* Postoperative patients with gastric cancer invading the mucosa and submucosal layer and having less than 3 lymph nodes metastasis or who with gastric cancer infiltration of muscularis propria without lymph node metastasis (stage II and III advanced gastric cancer patients, 8th of the AJCC)
* Patients who have received neoadjuvant chemotherapy or radiotherapy
* Patients without pathological record and clinical information after surgery from archived FFPE samples between 2005 and 2010
* Patients who have been included in discovery clinical trial and confirmatory clinical trial
* Patients with residual tumors after surgery
2. Sample criteria
* The FFPE tumor specimens in storage have a tumor amount of less than 20% and therefore cannot be tested
* The quantity and quality of RNA are not sufficient for analysis
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novomics. Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Young-Woo Kim, MD., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
National Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novomics. Co., Ltd.
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NM-CTP-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.